Nasdaq28d
Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook - Update
(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.
Yahoo Finance28d
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024 ...
C&EN28d
Rational Design of a Quasi-Metal–Organic Framework by Ligand Engineering for Efficient Biomass Upgrading
Shenzhen Key Laboratory of Micro/Nano-Porous Functional Materials (SKLPM), Southern University of Science and Technology, Shenzhen 518055, China Department of Chemistry, Southern University of Science ...
C&EN1mon
Natural Language Processing Methods for the Study of Protein–Ligand Interactions
You are free to share (copy and redistribute) this article in any medium or format within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must ...
Wall Street Journal4y
Ligand Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...